Recent:Gavriilidis.
Apr 28 |
Dornase alfa for COVID-19: real-time meta analysis of 3 studies | |
| Meta analysis using the most serious outcome reported shows 12% [-34‑87%] higher risk, without reaching statistical significance. Currently all studies are RCTs. Currently there is limited data, with only 242 patients and only .. | ||
Apr 24 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaf246 | Aerosolized dornase alfa (DNase I) for the treatment of severe respiratory failure in COVID-19: a randomized controlled trial |
| 11% higher mortality (p=1) and 2% worse recovery (p=0.94). RCT 76 hospitalized COVID-19 patients showing no significant difference with inhaled dornase alfa (DNase I) for resolution of hypoxia or other clinical outcomes. | ||
Jul 16 2024 |
et al., eLife, doi:10.7554/eLife.87030.4 | Anti-inflammatory therapy with nebulized dornase alfa for severe COVID-19 pneumonia: a randomized unblinded trial |
| 130% higher mortality (p=1) and 10% higher hospital discharge (p=1). RCT 99 hospitalized COVID-19 patients showing significantly reduced C-reactive protein (CRP) levels and length of hospital stay with nebulized dornase alfa treatment in addition to standard of care (dexamethasone). Authors combine the ran.. | ||
Mar 3 2023 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889 | Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial |
| 9% higher mortality (p=0.78) and 32% worse recovery (p=0.24). RCT severe COVID-19 patients showing no significant difference in outcomes with dornase alfa. | ||
Apr 18 2022 |
et al., Clinical Immunology, doi:10.1016/j.clim.2022.109016 | Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure |
| 74% lower mortality (p=0.05), 76% lower ventilation (p=0.02), and 20% shorter hospitalization (p=0.02). Small retrospective study of hospitalized patients with severe respiratory failure, 22 treated with a combination of budesonide, tocilizumab, baricitinib, dornase alfa, and salbutamol or/and ipratropium, and 26 SOC patients, showing lower.. | ||
Dec 31 2021 |
et al., NCT04402944 | Pulmozyme to Improve COVID-19 ARDS Outcomes |
| Estimated 60 patient dornase alfa late treatment RCT with results not reported over 3 years after estimated completion. | ||
Dec 20 2021 |
et al., NCT04355364 | Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19 |
| 77 patient dornase alfa late treatment RCT with results not reported over 3 years after completion. | ||
Sep 25 2020 |
et al., NCT04432987 | Determination of Dornase Alpha Effectiveness in COVID-19 Treatment |
| Estimated 60 patient dornase alfa late treatment RCT with results not reported over 4 years after estimated completion. | ||
Jul 20 2020 |
et al., NCT04459325 | A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 |
| 100 patient dornase alfa late treatment RCT with results not reported over 4 years after completion. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.